Logo image of BIO3.DE

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Stock Fundamental Analysis

FRA:BIO3 - Deutsche Boerse Ag - DE0005227235 - Currency: EUR

30  0 (0%)

Fundamental Rating

5

Overall BIO3 gets a fundamental rating of 5 out of 10. We evaluated BIO3 against 71 industry peers in the Biotechnology industry. BIO3 has only an average score on both its financial health and profitability. BIO3 has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year BIO3 was profitable.
BIO3 had a positive operating cash flow in the past year.
In the past 5 years BIO3 reported 4 times negative net income.
In the past 5 years BIO3 reported 4 times negative operating cash flow.
BIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFBIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

1.2 Ratios

BIO3 has a Return On Assets of 13.97%. This is amongst the best in the industry. BIO3 outperforms 94.37% of its industry peers.
BIO3 has a better Return On Equity (35.86%) than 95.77% of its industry peers.
BIO3 has a Return On Invested Capital of 15.05%. This is amongst the best in the industry. BIO3 outperforms 92.96% of its industry peers.
Industry RankSector Rank
ROA 13.97%
ROE 35.86%
ROIC 15.05%
ROA(3y)0.14%
ROA(5y)-0.57%
ROE(3y)-0.13%
ROE(5y)-1.74%
ROIC(3y)N/A
ROIC(5y)N/A
BIO3.DE Yearly ROA, ROE, ROICBIO3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 -20 30

1.3 Margins

The Profit Margin of BIO3 (23.75%) is better than 91.55% of its industry peers.
BIO3's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 28.40%, BIO3 belongs to the best of the industry, outperforming 92.96% of the companies in the same industry.
In the last couple of years the Operating Margin of BIO3 has grown nicely.
With a decent Gross Margin value of 46.62%, BIO3 is doing good in the industry, outperforming 61.97% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO3 has grown nicely.
Industry RankSector Rank
OM 28.4%
PM (TTM) 23.75%
GM 46.62%
OM growth 3YN/A
OM growth 5Y40.83%
PM growth 3YN/A
PM growth 5Y-16.36%
GM growth 3Y15.07%
GM growth 5Y3.99%
BIO3.DE Yearly Profit, Operating, Gross MarginsBIO3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BIO3 is creating value.
BIO3 has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIO3 has more shares outstanding
BIO3 has a better debt/assets ratio than last year.
BIO3.DE Yearly Shares OutstandingBIO3.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
BIO3.DE Yearly Total Debt VS Total AssetsBIO3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

2.2 Solvency

BIO3 has an Altman-Z score of 2.65. This is not the best score and indicates that BIO3 is in the grey zone with still only limited risk for bankruptcy at the moment.
BIO3 has a better Altman-Z score (2.65) than 77.46% of its industry peers.
The Debt to FCF ratio of BIO3 is 5.23, which is a neutral value as it means it would take BIO3, 5.23 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BIO3 (5.23) is better than 88.73% of its industry peers.
A Debt/Equity ratio of 0.80 indicates that BIO3 is somewhat dependend on debt financing.
The Debt to Equity ratio of BIO3 (0.80) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 5.23
Altman-Z 2.65
ROIC/WACC2.31
WACC6.53%
BIO3.DE Yearly LT Debt VS Equity VS FCFBIO3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

BIO3 has a Current Ratio of 2.45. This indicates that BIO3 is financially healthy and has no problem in meeting its short term obligations.
BIO3 has a Current ratio (2.45) which is in line with its industry peers.
A Quick Ratio of 0.88 indicates that BIO3 may have some problems paying its short term obligations.
BIO3's Quick ratio of 0.88 is on the low side compared to the rest of the industry. BIO3 is outperformed by 69.01% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 0.88
BIO3.DE Yearly Current Assets VS Current LiabilitesBIO3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

BIO3 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.71%, which is quite impressive.
The Earnings Per Share has been decreasing by -6.87% on average over the past years.
Looking at the last year, BIO3 shows a decrease in Revenue. The Revenue has decreased by -8.51% in the last year.
The Revenue has been growing by 11.33% on average over the past years. This is quite good.
EPS 1Y (TTM)32.71%
EPS 3YN/A
EPS 5Y-6.87%
EPS Q2Q%-108.65%
Revenue 1Y (TTM)-8.51%
Revenue growth 3Y12.24%
Revenue growth 5Y11.33%
Sales Q2Q%-40.39%

3.2 Future

The Earnings Per Share is expected to decrease by -31.29% on average over the next years. This is quite bad
The Revenue is expected to grow by 2.49% on average over the next years.
EPS Next Y-103.15%
EPS Next 2Y-31.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.17%
Revenue Next 2Y2.49%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BIO3.DE Yearly Revenue VS EstimatesBIO3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BIO3.DE Yearly EPS VS EstimatesBIO3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2024 2025 0 1 -1

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

BIO3 is valuated rather expensively with a Price/Earnings ratio of 17.54.
Based on the Price/Earnings ratio, BIO3 is valued cheaper than 90.14% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.79. BIO3 is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 19.80, BIO3 is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO3 indicates a rather cheap valuation: BIO3 is cheaper than 88.73% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of BIO3 to the average of the S&P500 Index (21.38), we can say BIO3 is valued inline with the index average.
Industry RankSector Rank
PE 17.54
Fwd PE 19.8
BIO3.DE Price Earnings VS Forward Price EarningsBIO3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BIO3 is valued cheaply inside the industry as 91.55% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIO3 indicates a rather cheap valuation: BIO3 is cheaper than 92.96% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.95
EV/EBITDA 6.43
BIO3.DE Per share dataBIO3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The decent profitability rating of BIO3 may justify a higher PE ratio.
A cheap valuation may be justified as BIO3's earnings are expected to decrease with -31.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.29%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BIO3 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTEST AG-VORZUGSAKTIEN

FRA:BIO3 (4/14/2025, 2:07:12 PM)

30

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26
Earnings (Next)05-05 2025-05-05
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.19B
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 17.54
Fwd PE 19.8
P/S 1.47
P/FCF 9.95
P/OCF 9.95
P/B 2.22
P/tB 2.28
EV/EBITDA 6.43
EPS(TTM)1.71
EY5.7%
EPS(NY)1.52
Fwd EY5.05%
FCF(TTM)3.01
FCFY10.05%
OCF(TTM)3.01
OCFY10.05%
SpS20.45
BVpS13.54
TBVpS13.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.97%
ROE 35.86%
ROCE 21.38%
ROIC 15.05%
ROICexc 16.34%
ROICexgc 16.59%
OM 28.4%
PM (TTM) 23.75%
GM 46.62%
FCFM 14.74%
ROA(3y)0.14%
ROA(5y)-0.57%
ROE(3y)-0.13%
ROE(5y)-1.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y50.28%
ROICexc growth 3YN/A
ROICexc growth 5Y50.45%
OM growth 3YN/A
OM growth 5Y40.83%
PM growth 3YN/A
PM growth 5Y-16.36%
GM growth 3Y15.07%
GM growth 5Y3.99%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 5.23
Debt/EBITDA 1.62
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 7.14
Cash Conversion 44.9%
Profit Quality 62.07%
Current Ratio 2.45
Quick Ratio 0.88
Altman-Z 2.65
F-Score6
WACC6.53%
ROIC/WACC2.31
Cap/Depr(3y)77.8%
Cap/Depr(5y)86.44%
Cap/Sales(3y)4.7%
Cap/Sales(5y)5.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.71%
EPS 3YN/A
EPS 5Y-6.87%
EPS Q2Q%-108.65%
EPS Next Y-103.15%
EPS Next 2Y-31.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.51%
Revenue growth 3Y12.24%
Revenue growth 5Y11.33%
Sales Q2Q%-40.39%
Revenue Next Year-6.17%
Revenue Next 2Y2.49%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1037.96%
EBIT growth 3YN/A
EBIT growth 5Y56.78%
EBIT Next Year-53.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y145.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y145.47%
OCF growth 3YN/A
OCF growth 5YN/A